See more : Impac Mortgage Holdings, Inc. (IMPHO) Income Statement Analysis – Financial Results
Complete financial analysis of Abeona Therapeutics Inc. (ABEO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Abeona Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Crucial Innovations Corp. (CINV) Income Statement Analysis – Financial Results
- China SCE Group Holdings Limited (1966.HK) Income Statement Analysis – Financial Results
- I.C.P. Israel Citrus Plantations Ltd. (CTPL5.TA) Income Statement Analysis – Financial Results
- Tiemco Ltd. (7501.T) Income Statement Analysis – Financial Results
- KLA Corporation (KLAC) Income Statement Analysis – Financial Results
Abeona Therapeutics Inc. (ABEO)
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.50M | 1.41M | 3.00M | 10.00M | 0.00 | 3.00M | 837.00K | 889.00K | 1.04M | 925.00K | 2.04M | 4.40M | 1.85M | 481.00K | 352.00K | 291.00K | 57.00K | 0.00 | 0.00 | 549.00K | 1.30M | 1.15M | 243.00K | 107.00K | 15.00K | 100.00K | 435.00K | 167.00K | 2.95M |
| Cost of Revenue | 1.61M | 450.00K | 4.46M | 30.14M | 8.68M | 38.70M | 16.99M | 10.66M | 0.00 | 0.00 | 125.00K | 267.00K | 1.22M | 140.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 239.00K | 277.00K | 107.00K | 0.00 | 0.00 | 0.00 | 0.00 | 580.00K | 8.31M | 0.00 |
| Gross Profit | 1.90M | 964.00K | -1.46M | -20.14M | -8.68M | -35.70M | -16.15M | -9.77M | 1.04M | 925.00K | 1.92M | 4.14M | 632.00K | 341.00K | 352.00K | 291.00K | 57.00K | 0.00 | 0.00 | 310.00K | 1.02M | 1.04M | 243.00K | 107.00K | 15.00K | 100.00K | -145.00K | -8.15M | 2.95M |
| Gross Profit Ratio | 54.14% | 68.18% | -48.80% | -201.39% | 0.00% | -1,190.79% | -1,929.75% | -1,098.54% | 100.00% | 100.00% | 93.88% | 93.94% | 34.20% | 70.89% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 56.47% | 78.61% | 90.67% | 100.00% | 100.00% | 100.00% | 100.00% | -33.33% | -4,878.44% | 100.00% |
| Research & Development | 31.09M | 28.97M | 34.33M | 30.14M | 48.57M | 38.70M | 16.99M | 10.66M | 4.72M | 333.00K | 884.00K | 2.01M | 4.20M | 3.35M | 2.66M | 12.61M | 2.60M | 2.05M | 2.78M | 5.42M | 6.10M | 7.02M | 4.17M | 4.01M | 1.61M | 1.80M | 2.43M | 1.41M | 1.25M |
| General & Administrative | 19.00M | 17.26M | 22.80M | 23.78M | 20.71M | 20.11M | 10.94M | 13.29M | 14.32M | 3.71M | 0.00 | 6.02M | 583.00K | 4.51M | 7.11M | 4.34M | 957.00K | 0.00 | 4.64B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.49M | 0.00 | 0.00 | 0.00 | 3.12M | 0.00 | -4.63B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.00M | 17.26M | 22.80M | 23.78M | 20.71M | 20.11M | 10.94M | 13.29M | 14.32M | 3.71M | 4.83M | 6.02M | 4.08M | 4.51M | 7.11M | 4.34M | 4.08M | 2.81M | 4.64M | 3.20M | 2.51M | 2.28M | 1.96M | 1.74M | 1.47M | 1.50M | 1.78M | 1.94M | 1.35M |
| Other Expenses | 0.00 | 141.00K | 3.25M | 4.59M | 7.82M | 2.36M | 741.00K | 825.00K | 551.00K | 3.72M | 4.84M | 419.00K | 4.31M | 238.00K | 259.00K | 253.00K | 4.36M | 3.12M | 6.84M | 3.97M | 3.14M | 2.72M | 2.38M | 2.16M | 1.76M | 1.70M | 1.95M | 2.06M | 1.35M |
| Operating Expenses | 49.03M | 46.22M | 60.37M | 58.50M | 77.09M | 61.16M | 28.67M | 24.77M | 19.59M | 4.06M | 5.72M | 8.45M | 8.51M | 8.10M | 10.03M | 17.21M | 6.96M | 5.18M | 9.62M | 9.39M | 9.23M | 9.74M | 6.55M | 6.17M | 3.36M | 3.50M | 4.38M | 3.47M | 2.60M |
| Cost & Expenses | 50.64M | 46.67M | 60.37M | 58.50M | 77.09M | 61.16M | 28.67M | 24.77M | 19.59M | 4.06M | 5.85M | 8.72M | 9.72M | 8.24M | 10.03M | 17.21M | 6.96M | 5.18M | 9.62M | 9.63M | 9.51M | 9.85M | 6.55M | 6.17M | 3.36M | 3.50M | 4.96M | 11.78M | 2.60M |
| Interest Income | 2.12M | 431.00K | 69.00K | 1.30M | 1.21M | 1.51M | 525.00K | 2.01M | 4.03M | 45.00K | 251.00K | 242.00K | 1.33M | 2.05M | 29.00K | 178.00K | 125.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 418.00K | 736.00K | 3.67M | 4.12M | 400.00K | 11.00K | 8.00K | 6.00K | 6.00K | 582.00K | 279.00K | 608.00K | 963.00K | 607.00K | 539.00K | 478.00K | 3.51M | 7.44M | 2.10M | 1.39M | 1.28M | 1.28M | 1.17M | 342.00K | 0.00 | 0.00 | 0.00 | 45.00K | 0.00 |
| Depreciation & Amortization | 3.20M | 4.58M | 4.46M | 5.60M | 8.68M | 2.36M | 741.00K | 825.00K | 551.00K | 11.00K | 3.00K | 419.00K | 233.00K | 238.00K | 259.00K | 253.00K | 2.60M | 7.06M | 1.57M | 1.08M | 898.00K | 686.00K | 627.00K | 476.00K | 285.00K | 200.00K | 162.00K | 123.00K | 15.00K |
| EBITDA | -50.57M | -34.38M | -76.80M | -74.52M | -67.61M | -54.31M | -26.58M | -21.05M | -13.97M | -26.19M | 4.73M | -9.51M | -1.32M | -6.69M | -16.54M | -16.48M | -18.12M | 2.99M | -7.56M | -4.93M | -4.53M | -8.01M | -5.68M | -5.58M | -3.06M | -3.30M | -4.36M | -11.49M | 356.00K |
| EBITDA Ratio | -1,444.91% | -3,160.18% | -1,801.70% | -426.17% | 0.00% | -1,811.21% | -3,174.43% | -2,366.93% | -1,343.17% | -332.43% | -173.85% | -82.99% | -341.40% | -1,309.77% | -642.90% | -5,664.60% | 12,847.37% | 0.00% | 0.00% | -1,457.74% | -564.86% | -698.69% | -2,337.86% | -5,216.82% | -20,426.67% | -3,200.00% | -1,030.11% | -6,997.60% | 12.09% |
| Operating Income | -47.14M | -45.26M | -89.84M | -81.42M | -77.09M | -58.17M | -27.84M | -23.88M | -18.55M | -3.13M | -3.80M | -4.32M | -7.88M | -7.76M | -9.68M | -16.92M | -6.90M | -5.18M | -9.62M | -9.08M | -8.21M | -8.70M | -6.31M | -6.06M | -3.35M | -3.40M | -4.52M | -11.61M | 341.00K |
| Operating Income Ratio | -1,346.71% | -3,200.64% | -2,994.53% | -814.20% | 0.00% | -1,940.16% | -3,325.69% | -2,686.28% | -1,783.27% | -338.49% | -186.29% | -98.00% | -426.19% | -1,612.68% | -2,748.86% | -5,812.71% | -12,105.26% | 0.00% | 0.00% | -1,653.73% | -634.21% | -758.50% | -2,595.88% | -5,661.68% | -22,326.67% | -3,400.00% | -1,040.00% | -6,953.89% | 11.58% |
| Total Other Income/Expenses | -7.05M | 11.22M | 4.90M | -2.81M | 808.00K | 1.50M | 517.00K | 2.01M | 4.02M | -23.65M | 8.25M | -6.22M | 5.36M | 220.00K | -7.15M | -300.00K | -15.02M | -8.25M | -4.07M | -1.16M | 1.79M | -684.00K | 281.00K | 630.00K | 41.00K | 0.00 | 83.00K | 151.00K | 0.00 |
| Income Before Tax | -54.19M | -39.70M | -84.94M | -84.23M | -76.28M | -56.67M | -27.32M | -21.87M | -14.53M | -26.78M | 4.45M | -10.53M | -2.52M | -8.98M | -16.83M | -17.22M | -21.92M | 13.42M | -11.62M | -10.24M | -6.94M | -9.38M | -6.03M | -5.43M | -3.31M | 0.00 | -4.44M | -11.46M | 341.00K |
| Income Before Tax Ratio | -1,548.23% | -2,807.36% | -2,831.20% | -842.34% | 0.00% | -1,890.29% | -3,263.92% | -2,460.40% | -1,396.73% | -2,894.92% | 217.87% | -239.15% | -136.09% | -1,866.11% | -4,781.25% | -5,915.81% | -38,450.88% | 0.00% | 0.00% | -1,864.85% | -535.52% | -818.13% | -2,480.25% | -5,072.90% | -22,053.33% | 0.00% | -1,020.92% | -6,863.47% | 11.58% |
| Income Tax Expense | 0.00 | -7.89M | 3.67M | 4.12M | 400.00K | 1.51M | 525.00K | 2.01M | 4.03M | 582.00K | 279.00K | 608.00K | 17.00K | -220.00K | 7.66M | 178.00K | -61.00K | -173.00K | -4.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -83.00K | -151.00K | 0.00 |
| Net Income | -54.19M | -31.81M | -88.61M | -88.35M | -76.68M | -56.67M | -27.32M | -21.87M | -14.53M | -26.78M | 4.45M | -10.53M | -2.53M | -7.54M | -17.34M | -17.22M | -21.86M | -12.87M | -1.70M | -10.24M | -6.94M | -9.38M | -6.03M | -5.43M | -3.31M | -3.40M | -4.44M | -11.46M | 341.00K |
| Net Income Ratio | -1,548.23% | -2,249.58% | -2,953.53% | -883.49% | 0.00% | -1,890.29% | -3,263.92% | -2,460.40% | -1,396.73% | -2,894.92% | 217.87% | -239.15% | -137.01% | -1,566.94% | -4,926.14% | -5,915.81% | -38,343.86% | 0.00% | 0.00% | -1,864.85% | -535.52% | -818.13% | -2,480.25% | -5,072.90% | -22,053.33% | -3,400.00% | -1,020.92% | -6,863.47% | 11.58% |
| EPS | -2.53 | -4.05 | -22.50 | -23.84 | -38.07 | -29.81 | -16.40 | -16.00 | -13.16 | -344.56 | 76.75 | -544.49 | -158.39 | -602.67 | -1.83K | -2.58K | -7.69K | -4.56K | -656.62 | -4.22K | -3.27K | -4.48K | -2.93K | -3.07K | -3.40K | -6.20K | -317.21K | -955.17K | 37.89K |
| EPS Diluted | -2.53 | -4.05 | -22.50 | -23.84 | -38.07 | -29.81 | -16.40 | -16.00 | -13.16 | -344.56 | 76.00 | -544.49 | -158.39 | -602.67 | -1.83K | -2.58K | -7.69K | -4.56K | -656.62 | -4.22K | -3.27K | -4.48K | -2.93K | -3.07K | -3.40K | -6.20K | -317.21K | -955.17K | 37.89K |
| Weighted Avg Shares Out | 21.38M | 7.86M | 3.94M | 3.71M | 2.01M | 1.90M | 1.67M | 1.37M | 1.10M | 77.72K | 20.19K | 19.34K | 15.99K | 12.51K | 9.45K | 6.68K | 2.84K | 2.83K | 2.59K | 2.43K | 2.12K | 2.10K | 2.06K | 1.77K | 974.00 | 548.00 | 14.00 | 12.00 | 9.00 |
| Weighted Avg Shares Out (Dil) | 21.38M | 7.86M | 3.94M | 3.71M | 2.01M | 1.90M | 1.67M | 1.37M | 1.10M | 77.72K | 20.38K | 19.34K | 15.99K | 12.51K | 9.45K | 6.68K | 2.84K | 2.83K | 2.59K | 2.43K | 2.12K | 2.10K | 2.06K | 1.77K | 974.00 | 548.00 | 14.00 | 12.00 | 9.00 |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK, NY / ACCESSWIRE / June 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ:ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980,...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK , May 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Abeona Therapeutics to Present at the Jefferies Global Healthcare Conference
CLEVELAND, May 28, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its senior management team will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 11:30...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK , May 23, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK , May 16, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Abeona Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Progress
BLA resubmission anticipated in second half of 2024 Closed $75 million underwritten offering in May, extending expected cash runway into 2026 CLEVELAND, May 15, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today reported financial results for the first...
Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CLEVELAND, May 07, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
NEW YORK , May 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Abeona Therapeutics Announces Pricing of $75 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
CLEVELAND, May 03, 2024 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) (“Abeona” or the “Company”) today announced the pricing of an underwritten offering of 12,285,056 shares of its common stock and, in lieu of common stock, pre-funded warrants to...
Buying The Dip In Abeona Therapeutics After The Recent Manufacturing-Related CRL
Abeona Therapeutics is a gene therapy company with a lead product candidate, Pz-cel, for recessive epidermolysis bullosa, or RDEB. Pz-cel has shown higher efficacy than the competition in treating larger skin lesions in RDEB. Despite receiving a complete response letter...
Source: https://incomestatements.info
Category: Stock Reports